Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
Accelerating Glaucoma Drug Discovery: From Preclinical Models to Efficacy Validation
LIVE WEBINAR
Accelerating Glaucoma Drug Discovery: From Preclinical Models to Efficacy Validation
This webinar will introduce how to accelerate ophthalmic drug discovery. Using glaucoma as a case study, it covers preclinical model selection (e.g., OHT, ONC) and efficacy evaluation with in-vivo functional readouts (IOP, OCT, ERG) for therapeutics ranging from small molecules to gene therapies.
DATE
October 30, 2025 | 10:00 - 11:00 AM (PDT)
LOCATION
Online | Zoom

Webinar Summary

The development of new therapeutics for ophthalmic diseases, from glaucoma and AMD to dry eye, requires robust data from clinically relevant preclinical models. This webinar provides a practical guide for researchers across the field, using glaucoma as a deep-dive case study to illustrate the critical steps of model selection and efficacy validation. We will systematically cover how to leverage diverse preclinical models—including those for wet/dry AMD, dry eye, and RP models—to de-risk and accelerate the entire drug discovery pipeline for a wide range of therapeutic modalities.
Topic Covered
  • The Landscape of Glaucoma Preclinical Research
  • Developing Animal Models for Glaucoma Research
  • Efficacy Validation: Key In-Vivo Functional Readouts (IOP, OCT, ERG)
  • Case Studies: Applying Gene Therapies on Cyagen's Ophthalmic Platform
Who Should Attend
  • Ophthalmic Drug Discovery Professionals
  • Preclinical In Vivo Pharmacology Teams
  • Scientists and Researchers focused on glaucoma, retinal diseases, and neuroprotection.
Attend this Webinar to:
  • Select the optimal preclinical model for your therapeutic goal, from IOP-dependent (e.g., OHT) to IOP-independent (e.g., ONC) assays for neuroprotection.
  • Quantify therapeutic efficacy using in-vivo functional readouts (IOP, OCT, ERG) and validate these findings with terminal pathological analyses.
  • Apply these models to diverse therapeutic modalities through case studies on small molecules and AAV-based gene therapies.
  • Accelerate your R&D pipeline with an integrated, end-to-end preclinical solution.

Webinar Presenter

{{value.name}}
{{value.title}}
{{value.company}}
{{value.descript}}

Discover Our Solutions

{{ value.label }}
{{ value.name }}
Explore
Request Information About This Webinar
Whether you're joining live or catching up later, fill out the form to receive materials or updates related to this webinar.
Meeting Details
Which type of solutions are you considering?
When are you planning to start your project?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Main Area of Research
How did you hear about us?
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research